BJ Bioscience, a Hangzhou novel drug developer, has signed up CMAB Biopharma (Suzhou) to provide CMC research and manufacturing services for BJ-005, its bi-functional mAb intended for cancer indications. CMAB will develop BJ-005 to support INDs in China and the US. Previously, BJ Bio has submitted an IND for its lead candidate, BJ-105, a fusion IL-12 mAb, also targeting cancer. The company said it wants to focus on innovative discovery, while it uses CMAB’s experience in CMC and manufacturing to advance BJ-005.
Source: China Biotoday
